Kopp Family Office LLC Has $15.76 Million Stake in Vericel Co. (NASDAQ:VCEL)

Kopp Family Office LLC trimmed its stake in Vericel Co. (NASDAQ:VCEL - Free Report) by 18.5% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 372,948 shares of the biotechnology company's stock after selling 84,730 shares during the quarter. Vericel makes up about 10.2% of Kopp Family Office LLC's portfolio, making the stock its 3rd biggest holding. Kopp Family Office LLC owned 0.76% of Vericel worth $15,757,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in VCEL. Geneva Capital Management LLC raised its holdings in shares of Vericel by 61.4% in the 3rd quarter. Geneva Capital Management LLC now owns 1,104,386 shares of the biotechnology company's stock valued at $46,660,000 after purchasing an additional 420,078 shares during the period. Wellington Management Group LLP raised its stake in Vericel by 214.0% in the 3rd quarter. Wellington Management Group LLP now owns 587,857 shares of the biotechnology company's stock valued at $24,837,000 after acquiring an additional 400,667 shares during the period. Congress Asset Management Co. lifted its holdings in Vericel by 37.4% during the 3rd quarter. Congress Asset Management Co. now owns 1,291,720 shares of the biotechnology company's stock valued at $54,575,000 after purchasing an additional 351,550 shares during the last quarter. Federated Hermes Inc. boosted its position in Vericel by 34.9% during the second quarter. Federated Hermes Inc. now owns 840,787 shares of the biotechnology company's stock worth $38,575,000 after purchasing an additional 217,437 shares during the period. Finally, TimesSquare Capital Management LLC increased its holdings in shares of Vericel by 54.8% in the third quarter. TimesSquare Capital Management LLC now owns 590,145 shares of the biotechnology company's stock valued at $24,934,000 after purchasing an additional 209,009 shares during the last quarter.

Analyst Ratings Changes

VCEL has been the subject of a number of research reports. BTIG Research raised their target price on shares of Vericel from $56.00 to $66.00 and gave the stock a "buy" rating in a research note on Tuesday, November 26th. Stephens upgraded shares of Vericel to a "strong-buy" rating in a research report on Monday, December 2nd. StockNews.com raised Vericel from a "sell" rating to a "hold" rating in a research report on Tuesday, December 24th. Truist Financial lifted their price target on Vericel from $61.00 to $67.00 and gave the stock a "buy" rating in a report on Wednesday, December 18th. Finally, HC Wainwright restated a "buy" rating and issued a $60.00 price target on shares of Vericel in a research note on Friday, November 8th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $61.14.

Insider Buying and Selling

In other Vericel news, Director Steven C. Gilman sold 5,833 shares of the business's stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $41.36, for a total transaction of $241,252.88. Following the completion of the transaction, the director now owns 11,000 shares of the company's stock, valued at approximately $454,960. The trade was a 34.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Dominick Colangelo sold 17,500 shares of the stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $41.38, for a total transaction of $724,150.00. Following the completion of the transaction, the chief executive officer now directly owns 220,937 shares of the company's stock, valued at $9,142,373.06. This trade represents a 7.34 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 44,266 shares of company stock valued at $2,090,636 over the last quarter. 5.20% of the stock is owned by company insiders.

Vericel Stock Performance

Shares of VCEL stock traded down $0.39 during trading on Tuesday, hitting $54.91. The company had a trading volume of 351,788 shares, compared to its average volume of 422,948. The stock's 50-day moving average price is $53.87 and its 200 day moving average price is $48.90. Vericel Co. has a one year low of $32.31 and a one year high of $61.49. The firm has a market capitalization of $2.71 billion, a P/E ratio of 915.32 and a beta of 1.71.

Vericel (NASDAQ:VCEL - Get Free Report) last released its earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.05) by $0.03. Vericel had a return on equity of 1.48% and a net margin of 1.56%. The firm had revenue of $57.91 million during the quarter, compared to the consensus estimate of $55.32 million. On average, research analysts anticipate that Vericel Co. will post 0.13 earnings per share for the current fiscal year.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.